perftoran profile

Perftoran is a perfluorocarbon emulsion used as a blood substitute. It is a colorless, odorless, and tasteless liquid that is chemically inert and does not dissolve in water. Perftoran is synthesized by the fluorination of hydrocarbons, which replaces all of the hydrogen atoms with fluorine atoms. The resulting compound has a high oxygen-carrying capacity and can be used to transport oxygen to tissues in the body. Perftoran has been studied for its potential use in a variety of medical applications, including as a blood substitute in trauma patients, as a contrast agent in medical imaging, and as a treatment for certain types of cancer. It is important to note that Perftoran has not been approved for use in the United States, but it is available in some other countries. The compound is still under investigation for its potential benefits and risks.'

ID Source	ID
PubMed CID	121961
MeSH ID	M0174883

Synonym
99752-82-6
perftoran
DTXSID50244230
Q4359344
iyvcxlagszwaeq-uhfffaoysa-n

Excerpt	Reference	Relevance
"Perftoran has a much smaller particle size resulting in milder adverse effects."	( Perftoran (Vidaphor)-Introduction to Western Medicine. Latson, GW, 2019)	2.68
"Perftoran, which has been rebranded as Vidaphor for marketing in North America, is an emulsion of perfluorocarbons in a surfactant and electrolyte mixture. "	( Perftoran (Vidaphor)-Introduction to Western Medicine. Latson, GW, 2019)	3.4
"Perftoran has no necrolytic and antibacterial properties and fails to make the terms of the 1st phase of the wound process shorter."	( [The use of a perfluorocarbon emulsion in the local treatment of wounds complicated by a surgical infection]. Khomenchuk, AI; Khrupkin, VI; Moroz, VV; Pisarenko, LV, 1997)	1.02

Excerpt	Reference	Relevance
" With respect to pentoxifylline and ciprofloxacin, which are less hydrophilic, the effect of pharmacokinetic interference was either weaker or absent."	( [Influence of perftoran on pharmacokinetics of hydrophilic drugs]. Pshenkina, NN, 2011)	0.73

Excerpt	Relevance	Reference
" Application of perftoran in 20 ml/kg dosage had promoted the APP and the non-reversible ischemic nonocclusive PG damage occurrence and prophylaxis."	( [Acute postoperative pancreatitis and hypertension of the pancreatic vascular system during hemorrhage in the course of the experiment]. Uzhva, VP, 1999)	0.65

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	10 (15.15)	18.2507
2000's	43 (65.15)	29.6817
2010's	13 (19.70)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	18 (18.00%)	5.53%
Reviews	8 (8.00%)	6.00%
Case Studies	1 (1.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	73 (73.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
lactic acid Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed). 2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.	2.05	1	0	2-hydroxy monocarboxylic acid	algal metabolite; Daphnia magna metabolite
histamine [no description available]	2.02	1	0	aralkylamino compound; imidazoles	human metabolite; mouse metabolite; neurotransmitter
niacinamide nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.	2.05	1	0	pyridine alkaloid; pyridinecarboxamide; vitamin B3	anti-inflammatory agent; antioxidant; cofactor; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor; EC 3.5.1.98 (histone deacetylase) inhibitor; Escherichia coli metabolite; geroprotector; human urinary metabolite; metabolite; mouse metabolite; neuroprotective agent; Saccharomyces cerevisiae metabolite; Sir2 inhibitor
verapamil Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.. verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.. 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.	2.07	1	0	aromatic ether; nitrile; polyether; tertiary amino compound
ciprofloxacin Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.. ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.	2.06	1	0	aminoquinoline; cyclopropanes; fluoroquinolone antibiotic; N-arylpiperazine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone; zwitterion	antibacterial drug; antiinfective agent; antimicrobial agent; DNA synthesis inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; environmental contaminant; topoisomerase IV inhibitor; xenobiotic
ketorolac Ketorolac: A pyrrolizine carboxylic acid derivative structurally related to INDOMETHACIN. It is an NSAID and is used principally for its analgesic activity. (From Martindale The Extra Pharmacopoeia, 31st ed). ketorolac : A racemate comprising equimolar amounts of (R)-(+)- and (S)-(-)-5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid. While only the (S)-(-) enantiomer is a COX1 and COX2 inhibitor, the (R)-(+) enantiomer exhibits potent analgesic activity. A non-steroidal anti-inflammatory drug, ketorolac is mainly used (generally as the tromethamine salt) for its potent analgesic properties in the short-term management of post-operative pain, and in eye drops to relieve the ocular itching associated with seasonal allergic conjunctivitis. It was withdrawn from the market in many countries in 1993 following association with haemorrhage and renal failure.. 5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid : A member of the class of pyrrolizines that is 2,3-dihydro-1H-pyrrolizine which is substituted at positions 1 and 5 by carboxy and benzoyl groups, respectively.	2.07	1	0	amino acid; aromatic ketone; monocarboxylic acid; pyrrolizines; racemate	analgesic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug
papaverine Papaverine: An alkaloid found in opium but not closely related to the other opium alkaloids in its structure or pharmacological actions. It is a direct-acting smooth muscle relaxant used in the treatment of impotence and as a vasodilator, especially for cerebral vasodilation. The mechanism of its pharmacological actions is not clear, but it apparently can inhibit phosphodiesterases and it may have direct actions on calcium channels.. papaverine : A benzylisoquinoline alkaloid that is isoquinoline substituted by methoxy groups at positions 6 and 7 and a 3,4-dimethoxybenzyl group at position 1. It has been isolated from Papaver somniferum.	2.07	1	0	benzylisoquinoline alkaloid; dimethoxybenzene; isoquinolines	antispasmodic drug; vasodilator agent
pentoxifylline [no description available]	2.06	1	0	oxopurine
adenosine diphosphate Adenosine Diphosphate: Adenosine 5'-(trihydrogen diphosphate). An adenine nucleotide containing two phosphate groups esterified to the sugar moiety at the 5'-position.	2.02	1	0	adenosine 5'-phosphate; purine ribonucleoside 5'-diphosphate	fundamental metabolite; human metabolite
perfluorodecalin perfluorodecalin: RN given refers to parent cpd without isomeric designation. perfluorodecalin : A fluorocarbon that is decalin in which every hydrogen is replaced by fluorine. Capable of dissolving large quantities of oxygen, it has been used as the basis of an artificial blood substitute.	2.01	1	0	fluorocarbon	blood substitute; solvent
malondialdehyde Malondialdehyde: The dialdehyde of malonic acid.. malonaldehyde : A dialdehyde that is propane substituted by two oxo groups at the terminal carbon atoms respectively. A biomarker of oxidative damage to lipids caused by smoking, it exists in vivo mainly in the enol form.	2.05	1	0	dialdehyde	biomarker
bendazole bendazole: also an NSAID; Russian drug; RN given refers to parent cpd; structure	2.07	1	0	benzimidazoles
silver nitrate Silver Nitrate: A silver salt with powerful germicidal activity. It has been used topically to prevent OPHTHALMIA NEONATORUM.	2.02	1	0	inorganic nitrate salt; silver salt	astringent
ozone Ozone: The unstable triatomic form of oxygen, O3. It is a powerful oxidant that is produced for various chemical and industrial uses. Its production is also catalyzed in the ATMOSPHERE by ULTRAVIOLET RAY irradiation of oxygen or other ozone precursors such as VOLATILE ORGANIC COMPOUNDS and NITROGEN OXIDES. About 90% of the ozone in the atmosphere exists in the stratosphere (STRATOSPHERIC OZONE).. ozone : An elemental molecule with formula O3. An explosive, pale blue gas (b.p. -112degreeC) that has a characteristic, pungent odour, it is continuously produced in the upper atmosphere by the action of solar ultraviolet radiation on atmospheric oxygen. It is an antimicrobial agent used in the production of bottled water, as well as in the treatment of meat, poultry and other foodstuffs.	4.18	3	1	elemental molecule; gas molecular entity; reactive oxygen species; triatomic oxygen	antiseptic drug; disinfectant; electrophilic reagent; greenhouse gas; mutagen; oxidising agent; tracer
daunorubicin Daunorubicin: A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS.. anthracycline : Anthracyclines are polyketides that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine.. daunorubicin : A natural product found in Actinomadura roseola.	2.01	1	0	aminoglycoside antibiotic; anthracycline; p-quinones; tetracenequinones	antineoplastic agent; bacterial metabolite
cefazolin Cefazolin: A semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine.. cefazolin : A first-generation cephalosporin compound having [(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl and (1H-tetrazol-1-ylacetyl)amino side-groups at positions 3 and 7 respectively.	2.06	1	0	beta-lactam antibiotic allergen; cephalosporin; tetrazoles; thiadiazoles	antibacterial drug
drotaverin drotaverin: Hungarian drug; RN given refers to parent cpd; structure	2.07	1	0	isoquinolines
myelin basic protein Myelin Basic Protein: An abundant cytosolic protein that plays a critical role in the structure of multilamellar myelin. Myelin basic protein binds to the cytosolic sides of myelin cell membranes and causes a tight adhesion between opposing cell membranes.	1.99	1	0
cefotaxime Cefotaxime: Semisynthetic broad-spectrum cephalosporin.. cefotaxime : A cephalosporin compound having acetoxymethyl and [2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino side groups.	2.06	1	0	1,3-thiazoles; cephalosporin; oxime O-ether	antibacterial drug; drug allergen
losartan potassium Erythropoietin: Glycoprotein hormone, secreted chiefly by the KIDNEY in the adult and the LIVER in the FETUS, that acts on erythroid stem cells of the BONE MARROW to stimulate proliferation and differentiation.	2.44	2	0
interleukin-8 Interleukin-8: A member of the CXC chemokine family that plays a role in the regulation of the acute inflammatory response. It is secreted by variety of cell types and induces CHEMOTAXIS of NEUTROPHILS and other inflammatory cells.	2.5	2	0
nov 002 NOV 002: a 1000-to-1 mixture of glutathione disulfide and cisplatin that is used to increase efficacy of chemotherapy against advanced non-small cell lung cancer; modulates cellular redox balance	3.89	2	1
flavin mononucleotide Flavin Mononucleotide: A coenzyme for a number of oxidative enzymes including NADH DEHYDROGENASE. It is the principal form in which RIBOFLAVIN is found in cells and tissues.	2.05	1	0
inosine diphosphate Inosine Diphosphate: An inosine nucleotide containing a pyrophosphate group esterified to C5 of the sugar moiety.	2.05	1	0	inosine phosphate; purine ribonucleoside 5'-diphosphate	fundamental metabolite

Condition	Relationship Strength	Studies	Trials
Atrophy of Gingiva [description not available]	2.08	1	0
Primary Peritonitis [description not available]	4.93	8	1
Peritonitis INFLAMMATION of the PERITONEUM lining the ABDOMINAL CAVITY as the result of infectious, autoimmune, or chemical processes. Primary peritonitis is due to infection of the PERITONEAL CAVITY via hematogenous or lymphatic spread and without intra-abdominal source. Secondary peritonitis arises from the ABDOMINAL CAVITY itself through RUPTURE or ABSCESS of intra-abdominal organs.	4.93	8	1
Brain Disorders [description not available]	2.04	1	0
Carbon Monoxide Poisoning Toxic asphyxiation due to the displacement of oxygen from oxyhemoglobin by carbon monoxide.	2.04	1	0
Brain Diseases Pathologic conditions affecting the BRAIN, which is composed of the intracranial components of the CENTRAL NERVOUS SYSTEM. This includes (but is not limited to) the CEREBRAL CORTEX; intracranial white matter; BASAL GANGLIA; THALAMUS; HYPOTHALAMUS; BRAIN STEM; and CEREBELLUM.	2.04	1	0
Acute Hepatic Failure [description not available]	2.04	1	0
Liver Failure, Acute A form of rapid-onset LIVER FAILURE, also known as fulminant hepatic failure, caused by severe liver injury or massive loss of HEPATOCYTES. It is characterized by sudden development of liver dysfunction and JAUNDICE. Acute liver failure may progress to exhibit cerebral dysfunction even HEPATIC COMA depending on the etiology that includes hepatic ISCHEMIA, drug toxicity, malignant infiltration, and viral hepatitis such as post-transfusion HEPATITIS B and HEPATITIS C.	2.04	1	0
Cerebral Ischemia [description not available]	3.43	1	1
Complication, Intraoperative [description not available]	3.81	2	1
Diseases, Peripheral Vascular [description not available]	3.43	1	1
Brain Ischemia Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION.	3.43	1	1
Peripheral Vascular Diseases Pathological processes involving any one of the BLOOD VESSELS in the vasculature outside the HEART.	3.43	1	1
Cardiovascular Stroke [description not available]	2.45	2	0
Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).	7.45	2	0
Infection, Postoperative Wound [description not available]	2.05	1	0
Acute Necrotizing Pancreatitis [description not available]	2.43	2	0
Jaundice, Cholestatic [description not available]	3.83	2	1
Hepatic Insufficiency Conditions in which the LIVER functions fall below the normal ranges. Severe hepatic insufficiency may cause LIVER FAILURE or DEATH. Treatment may include LIVER TRANSPLANTATION.	3.43	1	1
Jaundice, Obstructive Jaundice, the condition with yellowish staining of the skin and mucous membranes, that is due to impaired BILE flow in the BILIARY TRACT, such as INTRAHEPATIC CHOLESTASIS, or EXTRAHEPATIC CHOLESTASIS.	3.83	2	1
Adult Periodontitis [description not available]	2.05	1	0
Anoxemia [description not available]	4.89	4	2
Cardiac Failure [description not available]	2.05	1	0
Acute Disease Disease having a short and relatively severe course.	2.93	4	0
Hypoxia Sub-optimal OXYGEN levels in the ambient air of living organisms.	9.89	4	2
Heart Failure A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.	2.05	1	0
Cochlear Hearing Loss [description not available]	2.05	1	0
Deafness, Sudden Complete sensorineural hearing loss which develops suddenly over a period of hours or a few days.	2.05	1	0
Hearing Loss, Sensorineural Hearing loss resulting from damage to the COCHLEA and the sensorineural elements which lie internally beyond the oval and round windows. These elements include the AUDITORY NERVE and its connections in the BRAINSTEM.	2.05	1	0
Benign Neoplasms [description not available]	2.06	1	0
Blood Loss, Surgical Loss of blood during a surgical procedure.	2.44	2	0
Anemia A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.	2.06	1	0
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	2.06	1	0
Hemorrhagic Shock [description not available]	2.01	1	0
Ischemia A hypoperfusion of the BLOOD through an organ or tissue caused by a PATHOLOGIC CONSTRICTION or obstruction of its BLOOD VESSELS, or an absence of BLOOD CIRCULATION.	5.23	4	3
Acute Liver Injury, Drug-Induced [description not available]	2.01	1	0
Chemical and Drug Induced Liver Injury A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.	2.01	1	0
Viral Hepatitis, Human [description not available]	3.4	1	1
Hepatitis, Viral, Human INFLAMMATION of the LIVER in humans due to infection by VIRUSES. There are several significant types of human viral hepatitis with infection caused by enteric-transmission (HEPATITIS A; HEPATITIS E) or blood transfusion (HEPATITIS B; HEPATITIS C; and HEPATITIS D).	3.4	1	1
Air Embolism [description not available]	4.04	5	0
Embolism, Pulmonary [description not available]	2.02	1	0
Pulmonary Embolism Blocking of the PULMONARY ARTERY or one of its branches by an EMBOLUS.	2.02	1	0
Thoracic Diseases Disorders affecting the organs of the thorax.	7.02	1	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.43	2	0
Adhesions, Tissue [description not available]	2.01	1	0
Complication, Postoperative [description not available]	2.41	2	0
Postoperative Complications Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery.	2.41	2	0
Arm Injuries General or unspecified injuries involving the UPPER ARM and the FOREARM.	2.93	1	0
Crush Syndrome Severe systemic manifestation of trauma and ischemia involving soft tissues, principally skeletal muscle, due to prolonged severe crushing. It leads to increased permeability of the cell membrane and to the release of potassium, enzymes, and myoglobin from within cells. Ischemic renal dysfunction secondary to hypotension and diminished renal perfusion results in acute tubular necrosis and uremia.	2.93	1	0
Injuries, Leg [description not available]	2.93	1	0
Pericementitis [description not available]	2.02	1	0
Periodontitis Inflammation and loss of connective tissues supporting or surrounding the teeth. This may involve any part of the PERIODONTIUM. Periodontitis is currently classified by disease progression (CHRONIC PERIODONTITIS; AGGRESSIVE PERIODONTITIS) instead of age of onset. (From 1999 International Workshop for a Classification of Periodontal Diseases and Conditions, American Academy of Periodontology)	2.02	1	0
Injury, Ischemia-Reperfusion [description not available]	2.02	1	0
Reperfusion Injury Adverse functional, metabolic, or structural changes in tissues that result from the restoration of blood flow to the tissue (REPERFUSION) following ISCHEMIA.	7.02	1	0
Infections, Respiratory [description not available]	3.41	1	1
Respiratory Tract Infections Invasion of the host RESPIRATORY SYSTEM by microorganisms, usually leading to pathological processes or diseases.	3.41	1	1
Bends [description not available]	2.94	1	0
Phlegmon [description not available]	4.67	3	2
Dental Focal Infection [description not available]	4.67	3	2
Cellulitis An acute, diffuse, and suppurative inflammation of loose connective tissue, particularly the deep subcutaneous tissues, and sometimes muscle, which is most commonly seen as a result of infection of a wound, ulcer, or other skin lesions.	4.67	3	2
Innate Inflammatory Response [description not available]	3.41	1	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	3.41	1	1
Maxillary Diseases Diseases involving the MAXILLA.	3.42	1	1
Chronic Illness [description not available]	2.03	1	0
Alcoholic Intoxication An acute brain syndrome which results from the excessive ingestion of ETHANOL or ALCOHOLIC BEVERAGES.	2.03	1	0
Drug Withdrawal Symptoms [description not available]	2.03	1	0
Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).	2.03	1	0
Substance Withdrawal Syndrome Physiological and psychological symptoms associated with withdrawal from the use of a drug after prolonged administration or habituation. The concept includes withdrawal from smoking or drinking, as well as withdrawal from an administered drug.	2.03	1	0
Abscess Accumulation of purulent material in tissues, organs, or circumscribed spaces, usually associated with signs of infection.	3.43	1	1
Critical Illness A disease or state in which death is possible or imminent.	3.42	1	1
Allergic Encephalomyelitis [description not available]	6.99	1	0
Delayed Hypersensitivity [description not available]	1.99	1	0
Apnea A transient absence of spontaneous respiration.	6.99	1	0
Injuries, Soft Tissue [description not available]	1.99	1	0
Infection, Wound [description not available]	1.99	1	0
Bleeding [description not available]	2	1	0
Blood Pressure, Low [description not available]	2	1	0
Acute Edematous Pancreatitis [description not available]	2	1	0
Hemorrhage Bleeding or escape of blood from a vessel.	2	1	0
Hypotension Abnormally low BLOOD PRESSURE that can result in inadequate blood flow to the brain and other vital organs. Common symptom is DIZZINESS but greater negative impacts on the body occur when there is prolonged depravation of oxygen and nutrients.	2	1	0
Necrosis The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.	2	1	0
Pancreatitis INFLAMMATION of the PANCREAS. Pancreatitis is classified as acute unless there are computed tomographic or endoscopic retrograde cholangiopancreatographic findings of CHRONIC PANCREATITIS (International Symposium on Acute Pancreatitis, Atlanta, 1992). The two most common forms of acute pancreatitis are ALCOHOLIC PANCREATITIS and gallstone pancreatitis.	2	1	0
Shock, Traumatic Shock produced as a result of trauma.	2	1	0
Burns Injuries to tissues caused by contact with heat, steam, chemicals (BURNS, CHEMICAL), electricity (BURNS, ELECTRIC), or the like.	2	1	0
Pus [description not available]	2	1	0
Curling Ulcer Acute stress DUODENAL ULCER, usually observed in patients with extensive third-degree burns.	2	1	0
Hemorrhage, Peptic Ulcer [description not available]	2	1	0
Gastric Ulcer [description not available]	2	1	0
Duodenal Ulcer A PEPTIC ULCER located in the DUODENUM.	2	1	0
Stomach Ulcer Ulceration of the GASTRIC MUCOSA due to contact with GASTRIC JUICE. It is often associated with HELICOBACTER PYLORI infection or consumption of nonsteroidal anti-inflammatory drugs (NSAIDS).	2	1	0
Disease Exacerbation [description not available]	2	1	0
Disease, Pulmonary [description not available]	2	1	0
Lung Diseases Pathological processes involving any part of the LUNG.	2	1	0
Abnormality, Heart [description not available]	3.39	1	1
Heart Defects, Congenital Developmental abnormalities involving structures of the heart. These defects are present at birth but may be discovered later in life.	3.39	1	1
Acute Respiratory Distress Syndrome [description not available]	2.01	1	0
Symptom Cluster [description not available]	2.01	1	0
Respiratory Distress Syndrome A syndrome characterized by progressive life-threatening RESPIRATORY INSUFFICIENCY in the absence of known LUNG DISEASES, usually following a systemic insult such as surgery or major TRAUMA.	2.01	1	0
Syndrome A characteristic symptom complex.	7.01	1	0
Coronary Heart Disease [description not available]	1.97	1	0
Injury, Myocardial Reperfusion [description not available]	1.97	1	0
Coronary Disease An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.	1.97	1	0

perftoran

Cross-References

Synonyms (5)

Research Excerpts

Effects

Pharmacokinetics

Dosage Studied

Research

Studies (66)

Market Indicators

Research Demand Index: 32.98

Study Types